SI22888B - Polimorfi donepezil hidroklorida in postopek izdelave - Google Patents
Polimorfi donepezil hidroklorida in postopek izdelave Download PDFInfo
- Publication number
- SI22888B SI22888B SI9720102A SI9720102A SI22888B SI 22888 B SI22888 B SI 22888B SI 9720102 A SI9720102 A SI 9720102A SI 9720102 A SI9720102 A SI 9720102A SI 22888 B SI22888 B SI 22888B
- Authority
- SI
- Slovenia
- Prior art keywords
- polymorph
- donepezil hydrochloride
- donepezil
- manufacture
- hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Donepezil hidroklorid namreč benzil dimetoksi indanon il metilpiperidin hidroklorid je na voljo v obliki polimorfov ki so pri farmacevtski uporabi odporni proti toploti in vlagi Možno jih je industrijsko proizvajati Opredeljeniso z vrhovi vzorcev pri X žarkovni praškasi difrakciji ter z absorpcijskimi vrhovi pri infrardečem absorpcijskem spektru v kalijevem bromidu
Claims (14)
- Eisai Co., Ltd. Polimorfi donepezil hidroklorida in postopek izdelave PATENTNI ZAHTEVKI 1. Donepezil hidroklorid, namreč l-benzil-4-[(5,6-dimetoksi-l-indanon)-2-il]metilpiperidin hidroklorid, v obliki polimorfa (IV), pri čemer je polimorf opredeljen z vrhovi ob spodaj navedenih difrakcijskih stopnjah in spodaj navedeni intenziteti vzorcev praškaste X-žarkovne difrakcije, izraženi z I/I0, kot tudi spodaj navedenih absorpcijskih vrhov pri infrardečih absorpcijskih spektrih v kalijevem bromidu, izraženih v recipročnih centrimetrih, pri čemer velja polimorfi (IV) vrhovi pri praškastih X-žarkovnih difrakcijskih vzorcih so Difrakciiski koti (2Θ.°)_Intenziteta (I/L) 6,24 9,66 11,0412,12 12,54 12,76 13,98 14,42 14,88 15 12 22 24 67 61 27 15 11 2 16,34 12 17,46 100 18,12 25 18,60 32 19,06 15 19,98 74 20,24 41 20,62 34 21,30 48 21,80 63 22,58 78 23,04 46 24,00 32 24,54 49 25,14 90 25,36 99 26,06 34 28,10 41 28,58 39 29,30 31 29.44 28. Valovna števila (cm1) infrardečih absorpcijskih spektrov v kalijevem bromidu so: 401, 431, 459, 467, 490, 506, 518, 561, 586, 606, 631, 651, 709, 758, 766, 857, 944, 1009, 1041, 1106, 1119, 1132, 1213, 1225, 1265, 1304, 1318, 1429, 1458, 1470, 1500, 1589, 1605, 1630, 1647, 1683, 2562, 2577, 2608, 2634, 2689, 2717, 2836, 2924, 2949, 2989, 3007, 3032, 3061, 3322, 3376, 3422 cm '. 3
- 2. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak navlaženja v nadaljevanju definiranega polimorfa (II): (2) Polimorfi (II) Vrhovi v vzorcu praškaste X-žarkovne di frakcij e so: Intenziteta (I/Ll 8 100 13 40 38 38 35 17 20 17 19 19 47 24 19 33 22 25 27 18 14 Difrakciiski koti (2Θ.°) 7.40 9,88 12,36 15,54 16,10 16,22 16,48 17,30 18,04 18,44 18.84 19,34 19.84 21,16 22.40 23,18 24,02 24,92 25,72 26.40 27.22_ 4 Valovna števila (cm1) infrardečih absorpcijskih spektrov v kalijevem bromidu so: 699, 748, 762, 845, 947, 1009, 1035, 1067, 1103, 1118, 1129, 1174, 1193, 1206, 1222, 1247, 1267, 1317, 1365, 1422, 1436, 1456, 1465, 1502, 1592, 1607, 1688, 2412, 2489, 2627, 2846, 2868, 2913, 2928, 3435 cm1.
- 3. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak raztapljanja donepezila v vodi z dodajanjem tetrahidrofurana ali brez dodajanja le-tega ter z dodajanjem klorovodikove kisline ali vodikovega klorida raztopini.
- 4. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak raztapljanja donepezila v klorovodikovi kislini ter dodajanja tetrahidrofurana raztopini.
- 5. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak korak raztapljanja donepezila v toluenu ter dodajanja klorovodikove kisline raztopini.
- 6. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak raztapljanja donepezila v n-heksanu ter dodajanja klorovodikove kisline raztopini.
- 7. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak kristalizacije donepezila v mešanici metanola in klorovodikove kisline. 5
- 8. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak korak kristalizacije donepezila iz vode.
- 9. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak navlaženja amorfne oblike donepezil hidroklorida.
- 10. Postopek izdelave polimorfa (IV) donepezil hidroklorida po zahtevku 1, obsegajoč korak navlaženja polimorfa (II) donepezil hidroklorida
- 11. Uporaba farmakološko učinkovite količine donepezil hidroklorida v obliki polimorfa po zahtevku 1 za pripravo zdravila za zdravljenje bolezni, povezanih z acetilholinasterazno aktivnostjo.
- 12. Uporaba po zahtevku 11, pri čemer bolezen predstavlja senilna demenca.
- 13. Uporaba po zahtevku 11, pri čemer bolezen predstavlja senilna demenca Alzheimerjeve vrste.
- 14. Terapevtski sestavek, obsegajoč farmakološko učinkovito količino donepezil hidroklorida v obliki polimorfa po zahtevku 1 in farmakološko sprejemljiv nosilec.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14629396 | 1996-06-07 | ||
PCT/JP1996/003881 WO1997046526A1 (en) | 1996-06-07 | 1996-12-27 | Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production |
US08/774,802 US6140321A (en) | 1996-06-07 | 1996-12-30 | Polymorphs of donepezil hydrochloride and process for production |
PCT/JP1997/001932 WO1997046527A1 (en) | 1996-06-07 | 1997-06-06 | Polymorphs of donepezil hydrochloride and process for production |
Publications (2)
Publication Number | Publication Date |
---|---|
SI22888A SI22888A (sl) | 2010-04-30 |
SI22888B true SI22888B (sl) | 2010-06-30 |
Family
ID=15404413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9720102A SI22888B (sl) | 1996-06-07 | 1997-06-06 | Polimorfi donepezil hidroklorida in postopek izdelave |
Country Status (17)
Country | Link |
---|---|
US (1) | US6140321A (sl) |
JP (2) | JP2005015486A (sl) |
KR (1) | KR100545851B1 (sl) |
CN (1) | CN1312129C (sl) |
AT (1) | ATE445603T1 (sl) |
AU (1) | AU1153097A (sl) |
CA (1) | CA2516108C (sl) |
DE (1) | DE69739622D1 (sl) |
DK (1) | DK1211243T3 (sl) |
ES (1) | ES2330997T3 (sl) |
HK (1) | HK1080078A1 (sl) |
HU (1) | HUP0900417A3 (sl) |
PT (1) | PT1211243E (sl) |
SI (1) | SI22888B (sl) |
UA (1) | UA60307C2 (sl) |
WO (1) | WO1997046526A1 (sl) |
ZA (1) | ZA975064B (sl) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69805305T2 (de) * | 1997-08-21 | 2002-12-05 | P.N. Gerolymatos S.A., Kruoneri | Verwendung von phanquinon zur behandlung von alzheimer's krankheit |
AU9454098A (en) * | 1997-09-24 | 1999-04-12 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
PT1140090E (pt) | 1999-01-07 | 2005-05-31 | Gerolymatos P N Sa | Utilizacao de fanquinona para o tratamento ou prevencao da perda de memoria |
ATE277011T1 (de) * | 1999-03-03 | 2004-10-15 | Eisai Co Ltd | Flouride von 4-substituierten piperidin-derivaten |
WO2001066114A1 (en) | 2000-03-03 | 2001-09-13 | Eisai Co., Ltd. | Novel methods using cholinesterase inhibitors |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
DE60129828T2 (de) * | 2000-09-25 | 2008-04-30 | Eisai R&D Management Co., Ltd. | Verfahren zur herstellung eines multiform-kristalls von donepezil hydrochlorid |
US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
US20050142088A1 (en) * | 2002-02-07 | 2005-06-30 | Mitsuru Mizuno | Hair growth stimulants, percutaneous preparations and method of stimulating hair growth |
JP4336979B2 (ja) * | 2002-05-01 | 2009-09-30 | 三栄源エフ・エフ・アイ株式会社 | アラビアガムの改質方法 |
IL150509A (en) | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical preparations containing donafazil hydrochloride |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20060014801A1 (en) * | 2002-11-22 | 2006-01-19 | The Johns Hopkins University | Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs |
IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
US20050288330A1 (en) * | 2004-06-29 | 2005-12-29 | Avinash Naidu | Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) |
US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
WO2004092137A1 (en) * | 2003-04-16 | 2004-10-28 | Hetero Drugs Limited | Novel crystalline forms of donepezil hydrochloride |
WO2004099142A1 (en) * | 2003-05-05 | 2004-11-18 | Ranbaxy Laboratories Limited | Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
EP1776089A2 (en) * | 2003-12-31 | 2007-04-25 | Actavis Group hf | Donepezil formulations |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
WO2005112946A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor |
WO2006015338A2 (en) * | 2004-07-30 | 2006-02-09 | Dr. Reddy's Laboratories Ltd. | Crystalline form of donepezil hydrochloride |
US7371906B2 (en) * | 2004-08-24 | 2008-05-13 | Eastman Kodak Company | Process for photo-oxidative stability improvements |
AU2005288521A1 (en) * | 2004-09-29 | 2006-04-06 | Chemagis Ltd. | Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
NZ553804A (en) * | 2004-09-29 | 2010-07-30 | Bayer Schering Pharma Ag | Thermodynamically stable form of bay 43-9006 tosylate |
CA2584547C (en) * | 2004-10-19 | 2014-07-08 | Miha Vrbinc | Solid pharmaceutical composition comprising donepezil hydrochloride |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
CA2590533C (en) * | 2004-11-23 | 2010-09-07 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
US20060122226A1 (en) | 2004-12-08 | 2006-06-08 | Itai Adin | Crystalline forms of Donepezil base |
CN101087618A (zh) * | 2004-12-23 | 2007-12-12 | 航行药物公司 | 醋酸亮丙瑞林和乙酰胆碱酯酶抑制剂或nmda受体抑制剂在阿尔茨海默氏病治疗中的应用 |
US20060270709A1 (en) * | 2005-04-04 | 2006-11-30 | Eisai Co. Ltd. | Dihydropyridine compounds and compositions for headaches |
US20070026075A1 (en) * | 2005-07-28 | 2007-02-01 | Jutaro Shudo | Gelled donepezil compositions and methods for making and using the same |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
US7274339B2 (en) * | 2005-09-16 | 2007-09-25 | Smartant Telecom Co., Ltd. | Dual-band multi-mode array antenna |
DE102005060377A1 (de) | 2005-12-16 | 2007-06-21 | Ratiopharm Gmbh | Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung |
HU227474B1 (en) * | 2005-12-20 | 2011-07-28 | Richter Gedeon Nyrt | Process for industrial scale production of high purity donepezil hydrochloride polymorph i. |
WO2007108011A2 (en) * | 2006-03-20 | 2007-09-27 | Ind-Swift Laboratories Limited | Process for the preparation of highly pure donepezil |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
CN102838599A (zh) | 2006-05-04 | 2012-12-26 | 贝林格尔.英格海姆国际有限公司 | 多晶型 |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
JP5097359B2 (ja) * | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | ドネペジル経皮吸収型製剤 |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
AR063319A1 (es) * | 2006-10-16 | 2009-01-21 | Medichem Sa | Proceso mejorado para preparar la forma polimorfica i de clorhidrato de donepezilo (2,3-dihidro-5,6-dimetoxi-2-[[1-(fenilmetil)-4-piperidin]metil-1h-inden-1-ona) |
MX2009004516A (es) | 2006-10-27 | 2009-08-12 | Medivation Neurology Inc | Metodos y terapias de combinacion para tratar enfermedad de alzheimer. |
EP2081902A1 (en) * | 2006-11-09 | 2009-07-29 | Bayer Schering Pharma Aktiengesellschaft | Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
WO2008058644A1 (en) * | 2006-11-14 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
US20100099714A1 (en) * | 2007-03-05 | 2010-04-22 | Eisai R&D Management Co., Ltd. | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases |
JP2010524844A (ja) * | 2007-04-26 | 2010-07-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 認知症のためのシンナミド化合物 |
WO2009084030A2 (en) * | 2007-12-03 | 2009-07-09 | Neuland Laboratories Ltd. | Improved process for the preparation of (1-benzyl-4-(5,6,- dimethoxyind anone-2-yl)methylpiperidine) hydrochloride-form iii |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
AU2009290911A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JP5488956B2 (ja) * | 2008-11-25 | 2014-05-14 | 株式会社Dnpファインケミカル宇都宮 | (±)2−(ジメチルアミノ)−1−{〔O−(m−メトキシフェネチル)フェノキシ〕メチル}エチル水素サクシナート塩酸塩のI形結晶とII形結晶の混晶の製造法 |
AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
WO2011061591A1 (en) | 2009-11-18 | 2011-05-26 | Jubilant Life Sciences Limited | Improved process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanone)-2-yl)methyl piperidine hydrochloride form-iii |
KR102668834B1 (ko) | 2009-11-27 | 2024-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
IT1397912B1 (it) * | 2010-01-28 | 2013-02-04 | Chemi Spa | Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato. |
WO2011100373A1 (en) | 2010-02-09 | 2011-08-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
US20110251239A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
MX2012011604A (es) * | 2010-04-07 | 2013-02-27 | Onyx Therapeutics Inc | Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino. |
ES2935300T3 (es) | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | Combiterapia |
WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
US20130267560A1 (en) | 2010-10-22 | 2013-10-10 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
EA030121B1 (ru) | 2011-07-15 | 2018-06-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные хиназолины, их получение и их применение в фармацевтических композициях |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
CN103012247B (zh) * | 2013-01-18 | 2014-12-10 | 浙江东亚药业有限公司 | 一种盐酸多奈哌齐无水i晶型的制备方法 |
CN103965188A (zh) * | 2013-01-29 | 2014-08-06 | 中山大学 | 含硒多奈哌齐类似物 |
EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ, インコーポレイテッド | 認知機能を改善するための方法および組成物 |
CA2921308A1 (en) | 2013-08-16 | 2015-02-19 | Universiteit Maastricht | Treatment of cognitive impairment with pde4 inhibitor |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
CN106397306B (zh) * | 2016-10-20 | 2019-03-08 | 山东罗欣药业集团股份有限公司 | 一种盐酸多奈哌齐晶型化合物及其制备方法 |
US10369187B2 (en) | 2017-02-09 | 2019-08-06 | Vanderbilt University | Peptide regulators of JNK family kinases |
WO2020240505A1 (en) | 2019-05-31 | 2020-12-03 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Immediate release fixed-dose combination of memantine and donepezil |
WO2024145323A1 (en) | 2022-12-28 | 2024-07-04 | Corium, Llc | Pre-mixing method of preparing transdermal delivery system |
WO2024145319A1 (en) | 2022-12-28 | 2024-07-04 | Corium, Llc | Method of preparing transdermal delivery system |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
-
1996
- 1996-12-27 AU AU11530/97A patent/AU1153097A/en not_active Abandoned
- 1996-12-27 WO PCT/JP1996/003881 patent/WO1997046526A1/en active Application Filing
- 1996-12-30 US US08/774,802 patent/US6140321A/en not_active Expired - Fee Related
-
1997
- 1997-06-06 DE DE69739622T patent/DE69739622D1/de not_active Expired - Lifetime
- 1997-06-06 HU HU0900417A patent/HUP0900417A3/hu unknown
- 1997-06-06 AT AT02005248T patent/ATE445603T1/de active
- 1997-06-06 DK DK02005248.6T patent/DK1211243T3/da active
- 1997-06-06 UA UA99010107A patent/UA60307C2/uk unknown
- 1997-06-06 CN CNB200510075915XA patent/CN1312129C/zh not_active Expired - Fee Related
- 1997-06-06 KR KR1020047017860A patent/KR100545851B1/ko not_active IP Right Cessation
- 1997-06-06 ES ES02005248T patent/ES2330997T3/es not_active Expired - Lifetime
- 1997-06-06 SI SI9720102A patent/SI22888B/sl not_active IP Right Cessation
- 1997-06-06 CA CA002516108A patent/CA2516108C/en not_active Expired - Fee Related
- 1997-06-06 PT PT02005248T patent/PT1211243E/pt unknown
- 1997-06-09 ZA ZA9705064A patent/ZA975064B/xx unknown
-
2004
- 2004-07-12 JP JP2004205012A patent/JP2005015486A/ja active Pending
-
2006
- 2006-01-04 HK HK06100124A patent/HK1080078A1/xx not_active IP Right Cessation
-
2008
- 2008-08-04 JP JP2008201060A patent/JP2009040783A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
HK1080078A1 (en) | 2006-04-21 |
CN1699343A (zh) | 2005-11-23 |
CN1312129C (zh) | 2007-04-25 |
HU0900417D0 (en) | 2009-08-28 |
JP2009040783A (ja) | 2009-02-26 |
ATE445603T1 (de) | 2009-10-15 |
CA2516108C (en) | 2008-12-02 |
UA60307C2 (uk) | 2003-10-15 |
ZA975064B (en) | 1998-04-01 |
AU1153097A (en) | 1998-01-05 |
HUP0900417A3 (en) | 2012-12-28 |
ES2330997T3 (es) | 2009-12-18 |
KR20040104707A (ko) | 2004-12-10 |
WO1997046526A1 (en) | 1997-12-11 |
CA2516108A1 (en) | 1997-12-11 |
KR100545851B1 (ko) | 2006-01-24 |
DK1211243T3 (da) | 2010-02-08 |
PT1211243E (pt) | 2009-11-06 |
DE69739622D1 (de) | 2009-11-26 |
US6140321A (en) | 2000-10-31 |
SI22888A (sl) | 2010-04-30 |
JP2005015486A (ja) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI22888B (sl) | Polimorfi donepezil hidroklorida in postopek izdelave | |
SI9720038B (sl) | Polimorfi donepezil hidroklorida in postopek izdelave | |
AU2004281216B2 (en) | Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
DE3856491T2 (de) | Piperidin Derivate als anticholinerge Linkstoffe | |
US20030158415A1 (en) | Novel opiate compounds, methods of making and methods of use | |
NO312955B1 (no) | Sykliske aminderivater, farmasöytisk preparat og anvendelse av derivatene for fremstilling av et medikament | |
NO314354B1 (no) | Enantiomerrene estere, fremgangsmåte for deres fremstilling og deres anvendelse i legemidler | |
EP2358675B9 (en) | 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds | |
JP2007503423A (ja) | フェキソフェナジンの結晶多形、及びそれらを製造する方法 | |
PT1761492E (pt) | Oxalato de 1-benzil-4-[(5,6-dimetoxi-1-indanon)-2-il] metil-piperidina (oxalato de donepezil) e seus polimorfos | |
AU2009272303B2 (en) | Novel compounds active as muscarinic receptor antagonists | |
JPS6341901B2 (sl) | ||
JPH09508893A (ja) | シグマ受容体のリガンドである 新規2−アリールアルケニルアザシクロアルカン誘導体、その製造方法及び治療薬としてのその使用 | |
JPWO2002026709A1 (ja) | 塩酸ドネペジルの多形結晶の製造法 | |
EP2550252B1 (en) | 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds | |
DE2158077A1 (de) | Derivate des l-(3,3-Diphenyl-propyl)piperidins, ihre Herstellung und diese enthaltende Arzneimittel | |
NO20060377L (no) | Polymorfer av donepezilhydroklorid og fremgangsmater for deres fremstilling | |
US20050288330A1 (en) | Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) | |
Feng et al. | Syntheses of 3-carbomethoxy-4-(aryl) piperidines and In vitro and In vivo pharmacological evaluation: identification of inhibitors of the human dopamine transporter | |
JPH04500521A (ja) | ムスカリンレセプター拮抗薬 | |
NO319534B1 (no) | Mellomprodukt og fremgangsmater for fremstilling av antihistaminiske piperidinderivater og anvendelse derav for fremstilling av et medikament. | |
Hojahmat et al. | Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters | |
Clarke et al. | In pursuit of analgetic agents. Hydro-1, 3-ethanoindeno [2, 1-c] pyridines and homologs | |
DE60006698T2 (de) | Unsubstituierte ethyl- und propylderivate von phenoxythienoisoxazolen als d4 antagonisten | |
Maynard et al. | A convergent synthesis of 4-(2-benzothiazoyl) piperidines with antihistamic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20100515 |
|
KO00 | Lapse of patent |
Effective date: 20170301 |